Obesity & OverweightNCT07402031
Predicting Weight Loss After Pharmacological or Surgical Treatment in Patients With Obesity
An observational study of Obesity & Overweight, run by Université Catholique de Louvain at 1 site in Belgium.
Trial summary
As with other nutritional strategies, the clinical response to bariatric surgery can be highly variable, with weight regain being a frequent occurrence. Recent evidence on anti-obesity medication indicate similar inter-individual variability in clinical response. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Obesity & Overweight
- What is being tested?
- Pharmacological or surgical treament of obesity
- Type of treatment
- Surgery or procedure
- How many people
- 100 participants
- Where
- 1 siteBelgium
- Study dates
- 5 May 2026to Jan 2036
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants initiating an anti-obesity medication or candidates for bariatric surgery once its indication has been validated by a multidisciplinary committee, following medical, nutritional and psychological evaluations.
Who may be able to join
- Age between 18 and 65 years
- Obesity, with bariatric surgery indicated after a multidisciplinary evaluation in case of surgical treatment.
- Good physical and mental health, enabling informed consent.
- French speaker
Who cannot join
- Legal protection
- Pregnancy or breastfeeding
- History of bariatric surgery (except gastric banding, provided it was removed more than five years ago).
- Acute or progressive chronic disease
- Alcohol consumption of more than 20 g/day
- Inflammatory bowel disease;
Show all 11Show fewer
- Digestive autonomic diabetic neuropathy.
- Consumption of dietary supplements (stanols, probiotics, prebiotics or omega-3).
- Following a vegan or gluten-free diet or being lactose intolerant.
- Fibre consumption >30 g/day
- Recent change in antidiabetic medication within the past 3 months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Brussels Capital, 1200
Dr Yannick Deswysen, Doctor, +32 (0) 2 764 22 13, yannick.deswysen@saintluc.uclouvain.be
Yannick Deswysen, Doctor
About this study
Official title: Research of Predictive Factors of Weight Loss After Pharmacological or Surgical Treatment in Patients Suffering From Obesity
As with other nutritional strategies, the clinical response to bariatric surgery can be highly variable, with weight regain being a frequent occurrence. Recent evidence on anti-obesity medication indicate similar inter-individual variability in clinical response. Among multiples factors, co-occurrence of eating disorders such as binge eating disorder has been implicated in insufficient clinical response. Improving our ability to predict how patients will respond to obesity treatment is necessary in order to tailor the care pathways we offer. The mechanisms involved in disturbances of eating behaviour before and after surgery remain largely unknown. This study aims to identify the predictive factors of weight loss after pharmacological or surgical treatment, as well as the cognitive and biological mechanisms that mediate this effect.
- Conditions
- Obesity & Overweight
- Being tested
- Pharmacological or surgical treament of obesity
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pharmacological or surgical treament of obesityProcedure or surgery
Longitudinal follow-up of participants who initiate an anti-obesity medication or whose application for bariatric surgery was accepted. It will combine anthropometric, clinical, neuropsychological and biological measurements taken at various timepoints. Participants will be asked to complete a set of online questionnaires and data will be recorded anonymously. Biological samples will be collected at various time points.
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between weight loss after treatment and clinical, neuropsychological and biological parameters.
The percentage of excessive weight loss after treatment will be correlated with
- Clinical parameters (Binge Eating Scale and modified Yale Food Addiction Scale 2.0)
- Neuropsychological parameter (Barratt Impulsivness Scale and Trail Making Test)
- Biological parameters
Measured: Throughout the entire study, aproximately during 5 years
Secondary outcomes (11)
Binge Eating Disorder.
Evaluation of eating disorders using the Binge Eating Scale (BES).
Measured: Throughout the entire study, aproximately during 5 years
Food Addiction.
Evaluation of food addiction will be performed using modified Yale Food Addiction Scale 2.0.
Measured: Throughout the entire study, aproximately during 5 years
Eating attitudes
Eating patterns and habits will be screened using the Eating Attitude Test 26
Measured: Throughout the entire study, aproximately during 5 years
Cognitive flexibility.
Neuropsychological evaluation of cognitive flexibility will be performed with the Trail Making Test
Measured: Throughout the entire study, aproximately during 5 years
Impulsivity.
Impulsivity will be assessed using the Barrat Impulsiveness Scale (BIS)
Measured: Throughout the entire study, aproximately during 5 years
Self-reported quality of life.
Self-reported quality of life will be assessed using the QOLOD (Quality of Life, Obesity and Dietetics)
Measured: Throughout the entire study, aproximately during 5 years
Obesity.
Weight will be measured at each timepoint
Measured: Throughout the entire study, aproximately during 5 years
Physical activity.
Weekly physical activity will be reported with the Godin Leisure Time Exercise Questionnaire (GLTEQ)
Measured: Throughout the entire study, aproximately during 5 years
Food intake.
Eating habits will be recorded with a Food Frequency Questionnaire (FFQ)
Measured: Throughout the entire study, aproximately during 5 years
Blood samples
Blood samples will be collected and processed for metabolomic analyses.
Measured: Throughout the entire study, aproximately during 5 years
Fecal sample
Feces samples will be collected and processed to evaluation gut-microbiota composition
Measured: Throughout the entire study, aproximately during 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2026
- Study start5 May 2026
- Primary completionJun 2032 (estimated)
- Study completionJan 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity & OverweightStudies of the same condition, open and under way.
- More trials run by Université Catholique de LouvainThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université Catholique de Louvain
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Amandine Everard, Professor, Study director, Université Catholique de Louvain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07402031
- Sponsor's protocol ID
- TCAPrediBaria
- Status last verified
- May 2026
- First submitted
- 13 Jan 2026
- Last updated
- 14 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Research of Predictive Factors of Weight Loss After Pharmacological or Surgical Treatment in Patients Suffering From Obesity
- ClinicalTrials.gov ID
- NCT07402031
- Acronym / sponsor ID
- TCAPrediBaria
- Conditions
- Obesity & Overweight
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Université Catholique de LouvainUniversity, hospital or other
- Study start
- 5 May 2026 (actual)
- Primary completion
- Jun 2032 (estimated)
- Study completion
- Jan 2036 (estimated)
- First posted
- 11 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
As with other nutritional strategies, the clinical response to bariatric surgery can be highly variable, with weight regain being a frequent occurrence. Recent evidence on anti-obesity medication indicate similar inter-individual variability in clinical response. Among multiples factors, co-occurrence of eating disorders such as binge eating disorder has been implicated in insufficient clinical response. Improving our ability to predict how patients will respond to obesity treatment is necessary in order to tailor the care pathways we offer. The mechanisms involved in disturbances of eating behaviour before and after surgery remain largely unknown. This study aims to identify the predictive factors of weight loss after pharmacological or surgical treatment, as well as the cognitive and biological mechanisms that mediate this effect.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants initiating an anti-obesity medication or candidates for bariatric surgery once its indication has been validated by a multidisciplinary committee, following medical, nutritional and psychological evaluations.
Key inclusion criteria (4 listed)
- Age between 18 and 65 years
- Obesity, with bariatric surgery indicated after a multidisciplinary evaluation in case of surgical treatment.
- Good physical and mental health, enabling informed consent.
- French speaker
Key exclusion criteria (11 listed)
- Legal protection
- Pregnancy or breastfeeding
- History of bariatric surgery (except gastric banding, provided it was removed more than five years ago).
- Acute or progressive chronic disease
- Alcohol consumption of more than 20 g/day
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pharmacological or surgical treament of obesityLongitudinal follow-up of participants who initiate an anti-obesity medication or whose application for bariatric surgery was accepted. It will combine anthropometric, clinical, neuropsychological and biological measurements taken at various timepoints. Participants will be asked to complete a set of online questionnaires and data will be recorded anonymously. Biological samples will be collected at various time points. | Procedure or surgery | – |
Primary outcome
Correlation between weight loss after treatment and clinical, neuropsychological and biological parameters.
Time frame: Throughout the entire study, aproximately during 5 years
The percentage of excessive weight loss after treatment will be correlated with * Clinical parameters (Binge Eating Scale and modified Yale Food Addiction Scale 2.0) * Neuropsychological parameter (Barratt Impulsivness Scale and Trail Making Test) * Biological parameters
11 secondary outcomes
Binge Eating Disorder.
Time frame: Throughout the entire study, aproximately during 5 years
Food Addiction.
Time frame: Throughout the entire study, aproximately during 5 years
Eating attitudes
Time frame: Throughout the entire study, aproximately during 5 years
Cognitive flexibility.
Time frame: Throughout the entire study, aproximately during 5 years
Impulsivity.
Time frame: Throughout the entire study, aproximately during 5 years
Self-reported quality of life.
Time frame: Throughout the entire study, aproximately during 5 years
Obesity.
Time frame: Throughout the entire study, aproximately during 5 years
Physical activity.
Time frame: Throughout the entire study, aproximately during 5 years
Food intake.
Time frame: Throughout the entire study, aproximately during 5 years
Blood samples
Time frame: Throughout the entire study, aproximately during 5 years
Fecal sample
Time frame: Throughout the entire study, aproximately during 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity & Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Amandine Everard, Professor study director
Université Catholique de Louvain
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity & Overweight, run by Université Catholique de Louvain at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pr Amandine Everard, Professor (+ 32 (0)2 436 22 10 ext. +32, amandine.everard@uclouvain.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between weight loss after treatment and clinical, neuropsychological and biological parameters. (time frame: Throughout the entire study, aproximately during 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.